Back to Research Library
Compound Profiles 9 min read

TB-500: The Complete Research Guide

What actually happens inside your body when you take TB-500, the Wolverine Stack with BPC-157, and why it works systemically across the whole body.

What TB-500 Does Biologically

Seeks out dormant damage. TB-500 upregulates actin across cell populations throughout the body. Injuries that had plateaued begin to receive active biological attention again.

Promotes vascular development. New capillary formation occurs at damaged tissue sites. Blood flow and nutrient delivery are restored to areas that had become poorly supplied.

Targets inflammation specifically. Cytokine activity is reduced at wound sites without broad suppression of systemic immune function — a more targeted anti-inflammatory action than systemic interventions.

Mobilises regenerative cells. Signals bone marrow to release progenitor cell populations and directs their migration toward areas of tissue damage.

Acts across the whole body. Unlike BPC-157, which is typically administered near the injury site, TB-500 acts systemically — circulating throughout the body and addressing damage wherever it exists.

The BPC-157 and TB-500 Combination

The principle: Two tissue-repair peptides with distinct but complementary mechanisms, investigated together for synergistic regenerative effects.

BPC-157's role: Drives localised tissue repair — promotes soft tissue healing, reduces site-specific inflammation, and stimulates blood vessel growth at the injury location.

TB-500's role: Operates systemically — upregulates actin to support cell movement, promotes vascular development, and improves structural fibre alignment with reduced scar tissue formation.

Why the combination is studied: BPC-157 addresses the localised injury environment. TB-500 supports the whole-body context within which that repair takes place. Together they cover both targeted and systemic dimensions of the healing process.

Histological finding: Research in combination models suggests tissue heals with superior structural organisation — better fibre alignment, reduced chronic scarring, and greater structural integrity.

Biology After Stopping Various Peptides

BPC-157 and TB-500: The structural repairs these compounds appear to facilitate are durable. Repaired connective tissue maintains its integrity after administration ends. They serve a finite rather than indefinite function.

Semaglutide: Appetite signalling returns toward baseline within 2–4 weeks of discontinuation. Without lasting behavioural change, weight regain data suggests a mean of 60–70% recovery within one year.

Epitalon: Telomerase activation is transient. Sustained telomere maintenance appears to require periodic re-administration. Most published protocols describe cycles of 10–20 days, administered 2–3 times per year.

Semax and Selank: Cognitive and anxiolytic effects resolve within days of stopping. No withdrawal biology or dependency mechanisms have been documented. Effects are supportive rather than structural.

CJC-1295 and Ipamorelin: GH output gradually returns to pre-administration baseline. No suppression of endogenous GH production has been demonstrated. Body composition changes associated with elevated GH gradually reverse.

Biological Signs of Premature Ageing

Persistent fatigue despite adequate sleep. Growth hormone output declines approximately 15% per decade after the age of 30. Research into ipamorelin investigates restoration of natural GH pulsatility.

Slowed injury recovery. Tendons, joints, and soft tissue that previously healed in weeks now take months. BPC-157 research examines whether this trajectory can be accelerated at the cellular level.

Accelerated skin ageing appearance. GHK-Cu research documents modulation of more than 4,000 genes involved in collagen synthesis and tissue regeneration.

Increasing body fat on a stable diet. Semaglutide's published FDA-approved data document appetite signalling normalisation and reduced visceral fat accumulation.

Joint inflammation without identifiable cause. TB-500 research examines systemic anti-inflammatory activity and potential restoration of joint tissue flexibility.

Storage Guidelines

Store lyophilised TB-500 at -20°C. Following reconstitution with bacteriostatic water, store at 4°C. The reconstituted solution is stable for approximately 28 days. Protect from direct light at all stages.


For research and educational purposes only. Not approved for human therapeutic use.

Research Use Only: All products are sold strictly for in-vitro laboratory research purposes. Not for human or veterinary consumption. Not approved by the MHRA for any therapeutic use. Not intended to diagnose, treat, cure, or prevent any disease. Purchaser must be 18+ and a qualified researcher.

King Pharma

King Pharma is a UK-based supplier of independently verified, laboratory-grade peptide research compounds. All products are supplied for qualified scientific research use only.

⚠️ None of our products are intended for human use. No medicinal claims are made or implied.

© 2026 King Pharma Ltd. All rights reserved. Registered in England & Wales.

Secure payments:
VISAMCAMEXMaestro